AI assistant
FENNEC PHARMACEUTICALS INC. — Director's Dealing 2025
Nov 20, 2025
35599_dirs_2025-11-20_81463aac-8a05-4803-afc2-fabb02fa565c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: FENNEC PHARMACEUTICALS INC. (FENC)
CIK: 0001211583
Period of Report: 2025-11-18
Reporting Person: Southpoint Capital Advisors LP (10% Owner)
Reporting Person: Southpoint Capital Advisors LLC (10% Owner)
Reporting Person: Southpoint GP, LP (10% Owner)
Reporting Person: Southpoint GP, LLC (10% Owner)
Reporting Person: Clark John Smith II (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-11-18 | Common Stock | S | 19341 | $8.7921 | Disposed | 3744741 | Indirect |
Footnotes
F1: The securities are directly held by Southpoint Master Fund, LP for which Southpoint Capital Advisors LP serves as the investment manager and Southpoint GP, LP serves as the general partner. Southpoint Capital Advisors LLC serves as the general partner of Southpoint Capital Advisors LP and Southpoint GP, LLC serves as the general partner of Southpoint GP, LP. John S. Clark II serves as managing member of both Southpoint Capital Advisors LLC and Southpoint GP, LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.
F2: The transaction was executed in multiple trades at prices ranging from $8.75 to $8.845. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.